Related Experiment Video
Updated: Feb 2, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Abstract:
The experimental pan-AKT inhibitor capivasertib (AZD5363) helped stabilize or shrink tumor growth in most patients with metastatic AKT1-mutant tumors enrolled in the U.S.-wide NCI-MATCH trial, according to data presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Insights
The experimental drug capivasertib stabilized or shrank tumors in most patients with AKT1-mutant cancers. This AKT inhibitor shows promise for treating specific metastatic tumors.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Metastatic cancers with AKT1 mutations represent a targetable population for therapy.
- The NCI-MATCH trial investigated targeted therapies in patients with specific genetic alterations.
Discussion:
- Capivasertib, a pan-AKT inhibitor, demonstrated anti-tumor activity in patients with AKT1-mutant metastatic disease.
- Tumor stabilization or shrinkage was observed in a majority of treated patients.
Key Insights:
- Targeting AKT signaling with capivasertib is a viable strategy for AKT1-mutant cancers.
- The U.S.-wide NCI-MATCH trial provides crucial data on the efficacy of this experimental agent.
Outlook:
- Further clinical development of capivasertib for AKT1-mutant tumors is warranted.
- This finding may inform future treatment strategies for patients with similar molecular profiles.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms

